Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $19.4B | $20.2B | $21.8B | $5.4B | $5.9B | |
| Gross Profit | $8.2B | $9.2B | $9.9B | $2.5B | $2.8B | |
| Operating Income | $2.4B | $2.9B | $3.1B | $820M | $881M | |
| EBITDA | $4.6B | $5B | $5.4B | $1.3B | $1.4B | |
| Diluted EPS | $4.97 | $5.94 | $5.83 | $1.45 | $1.72 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.8B | $8.1B | $8.7B | $10.5B | $9.3B | |
| Total Assets | $53.9B | $52.9B | $52.8B | $57.3B | $55.3B | |
| Current Liabilities | $6.6B | $7.8B | $6.6B | $9B | $8.3B | |
| Total Liabilities | $30.2B | $27.7B | $27B | $31.4B | $29.9B | |
| Total Equity | $23.7B | $25.3B | $25.8B | $25.9B | $25.4B | |
| Total Debt | $18B | $16.4B | $16.3B | $20.8B | $19.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $3B | $3.8B | $3.4B | $1.2B | $1.4B | |
| Cash From Investing | -$716M | -$5.5B | -$818M | -$3.9B | -$494M | |
| Cash From Financing | -$2B | $2.1B | -$3.6B | $124M | -$809M | |
| Free Cash Flow | $2.1B | $3.1B | $2.7B | $882M | $1B | |
Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.
In the current month, BDX has received 3 Buy ratings 9 Hold ratings, and 0 Sell ratings. The BDX average analyst price target in the past 3 months is $204.83.
According to analysts, the consensus estimate is that Becton, Dickinson & Co. share price will rise to $204.83 per share over the next 12 months.
Analysts are divided on their view about Becton, Dickinson & Co. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Becton, Dickinson & Co. is a Sell and believe this share price will drop from its current level to $183.00.
The price target for Becton, Dickinson & Co. over the next 1-year time period is forecast to be $204.83 according to 12 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 9 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Becton, Dickinson & Co. is a Hold. 9 of 12 analysts rate the stock a Hold at this time.
You can purchase shares of Becton, Dickinson & Co. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Becton, Dickinson & Co. shares.
Becton, Dickinson & Co. was last trading at $205.38 per share. This represents the most recent stock quote for Becton, Dickinson & Co.. Yesterday, Becton, Dickinson & Co. closed at $198.96 per share.
In order to purchase Becton, Dickinson & Co. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $3.9T
P/E Ratio: 36x
Market Cap: $3.8T
P/E Ratio: 39x
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Innodata, Inc. [INOD] is up 4.84% over the past day.
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.